Navigation Links
New Study Shows Isolaz Can Reduce Acne Up to 90 Percent
Date:2/1/2008

Journal of Drugs in Dermatology Publishes Safety and Efficacy of Acne

Treatment

SANTA MONICA, Calif., Feb. 1 /PRNewswire-FirstCall/ -- Southern California-based dermatologist Ava Shamban, MD and co-investigators Mikiko Enokibori, MD, and Vic Narurkar, MD, conducted a global multi-center study using Isolaz to treat patients suffering from various degrees of acne, ranging from mild and moderate inflammatory acne to severe nodular and cystic acne.

The February edition of the Journal of Drugs in Dermatology will report the results of this study using the Isolaz device (Aesthera Corp(TM), Pleasanton, CA) for the treatment of mild to severe acne.

Prospective and retrospective data was collected from 56 patients who had undergone two to four treatments with a photopneumatic device (Isolaz). Evaluation criteria included lesion counts, using blinded physician evaluations of acne clearance, as well as treatment satisfaction surveys given to the participating physicians and patients.

In this study, 23 percent of patients had mild acne, 23 percent had moderate acne, 31 percent had severe nodular acne, and 8 percent had severe cystic acne. Results of the study demonstrated a 50 percent improvement in lesion counts post first treatment and a 90 percent improvement in lesion counts after the fourth treatment. Median acne severity (Burton Scale) decreased from level 4 before treatment to level 2 after final treatment. Median acne improvement was 4.5 (scale 1 - 5), and median acne clearance was 3 (scale 1 - 4). Erythema ratings decreased significantly with subsequent treatments and clinically significant adverse events were not reported. Both physician and patient satisfaction was high and increased with number of treatments given throughout the trial.

"The Isolaz system powered by photopneumatic technology provides severe acne sufferers with a safe and effective treatment option without the potential side effects associated with drug-based treatment alternatives," explains Dr. Shamban.

The unique mechanism of photopneumatic technology combines the proven therapeutic qualities of broadband light with pneumatic energy to physically evacuate the sebaceous gland. Dislodging the follicular ostia results in an almost immediate clearance of lesions 24 - 48 hours post treatment.

"Patients notice immediate improvement of acne that is not attainable with traditional medical therapies," notes co-investigator Dr. Narurkar. "In addition, painless and quick treatments with continued long-term improvement differentiate Isolaz treatments from other device-based treatments while contributing to high patient satisfaction levels," he adds.

About Ava T. Shamban, MD

Ava T. Shamban is Director of the Laser Institute for Dermatology and European Skin Care and assistant clinical professor at UCLA. For more about Dr. Shamban, visit: http://www.shamban-md.com

About Vic A. Narurkar, MD

Dr. Vic Narurkar is founder of the Bay Area Laser Institute in San Francisco, CA and assistant clinical professor at UC Davis. For more about Dr. Narurkar, visit: http://www.BayAreaLaserDr.com

About Mikiko Enokibori, MD

Dr. Mikiko Enokibori is founder of Mizuki Clinic in Otsu City, Shiga, Japan. For more about Dr. Enokibori, visit http://www.mizuki-clinic.com

About Isolaz

Isolaz is a painless device-based acne treatment powered by a breakthrough technology called photopneumatics (photo = light-based; pneumatics = vacuum) that combines vacuum with broadband light. Isolaz is the only device FDA cleared for the treatment of mild to moderate acne, including pustular and comedonal acne as well as mild to moderate inflammatory acne (acne vulgaris). Additionally, studies demonstrate that Isolaz treatments result in an immediate drying and flattening of lesions within 24 to 48 hours of treatment.

For more information about Isolaz treatments, visit http://www.Isolaz.com.


'/>"/>
SOURCE Ava Shamban, MD
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Journal Sleep: Study concludes a daytime nap can benefit a persons memory performance
2. MITs McGovern Institute researchers awarded $8.5M to study brain basis of autism and dyslexia
3. Study Spots Gene That Plays Role in Infertility
4. Kiadis Pharma Announces Successful Completion of Rhitol(TM) Phase II Clinical Study
5. Top hospitals have 27 percent lower mortality, annual HealthGrades study finds
6. Study reveals improved prediction of prostrate cancer
7. Porous structures help boost integration of host tissue with implants, study finds
8. UMass Medical School study finds patients diagnosed with coronary heart disease continue poor diets
9. Study paves way for development of macular degeneration cures
10. Study Challenges New Benchmark for High-Volume Heart Transplant Hospitals
11. Samarion(SM) Announces Formation of Outcome Based Study Team for Industrys Only Enterprise Quality Improvement System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... , ... Are You Concerned About Mold In Your Home or Workplace? ... Companies in VA, MD and DC, recently completed its application for the new District ... in the district of Columbia is a good thing stated John Taylor, Owner of ...
(Date:12/2/2016)... ... , ... On Dec. 2, 2016, CURE® magazine will host the 4th Annual ... MPN Heroes—eight individuals who have made a difference in the field of rare blood ... care, demonstrating leadership within the MPN community and/or a commitment to individual patients. , ...
(Date:12/2/2016)... ... December 02, 2016 , ... Center for Autism and Related Disorders (CARD) ... by autism spectrum disorder (ASD) and other developmental disabilities. The group, which is being ... and other caregivers the opportunity to share stories and advice, seek help, and continue ...
(Date:12/2/2016)... Beverly Hills, CA (PRWEB) , ... December 02, ... ... and reconstructive surgeon in Beverly Hills, California, will be included in the 2016 ... is given to exceptional professionals based on the amalgamation of their education, experience, ...
(Date:12/2/2016)... OH (PRWEB) , ... December 02, 2016 , ... ... of veterinarian diagnostic imaging systems and the first company to offer ... With a Heart at their tradeshow booth # 941 for the American Association ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... bioLytical Laboratories, ein Weltführer bei schnellen Tests für Infektionskrankheiten, hat sein ... eingeführt. Continue Reading ... ... , ... ) bioLytical wurde durch die Clinton Health Access ...
(Date:12/2/2016)... 2016   CytoSorbents Corporation (NASDAQ: CTSO ... Union approved CytoSorb ® cytokine adsorber to treat ... announced that Dr. Phillip Chan , Chief Executive ... Micro Main Event investor conference held from December ... Sunset Boulevard Hotel in Los Angeles, California ...
(Date:12/2/2016)... , Dec. 1, 2016  Today, Simpson Healthcare ... the honor of being selected as winners of multiple ... Healthcare Executives Website at the PLATINUM level, Blue Zones ... Module at the GOLD Level, and our proprietary 3ConneX ... At Simpson Healthcare Executives, we are excited to showcase ...
Breaking Medicine Technology: